https://doi.org/10.3350/cmh.2023.0553

Supplementary Table 2. Patient survival outcomes based on the duration of ATE+BEV treatment

	Death	Overall survival, months (95% CI)	*P*-value	Progression	Progression-free survival, months (95% CI)	*P*-value
Unadjusted cohort						
ATE+BEV treatment cycles ≤3						
Lenvatinib (n=9)	6/9 (66.7)	5.3 (3.5–NA)	0.952	9/9 (100.0)	3 (1.7–NA)	0.525
Sorafenib (n=44)	37/44 (84.1)	4.8 (4.1–7.9)		41/44 (93.2)	1.7 (1.5–2.1)	
ATE+BEV treatment cycles >3						
Lenvatinib (n=31)	13/31 (41.9)	13.3 (8–NA)	0.094	23/31 (74.2)	4 (3.5–6.3)	0.001
Sorafenib (n=42)	25/42 (59.5)	8.9 (5.5–13)		34/42 (81.0)	2.1 (1.7–2.7)	
PS-matched cohort						
ATE+BEV treatment cycles ≤3						
Lenvatinib (n=8)	6/8 (75.0)	4.65 (3.5–NA)	0.999	8/8 (100.0)	3.1 (1.7–NA)	0.317
Sorafenib (n=23)	19/23 (82.6)	5.2 (4.1–10.2)		21/23 (91.3)	1.8 (1.6–2.8)	
ATE+BEV treatment cycles >3						
Lenvatinib (n=28)	13/28 (46.4)	13.3 (8–NA)	0.655	21/28 (75.0)	4 (3–6.3)	0.059
Sorafenib (n=13)	6/13 (46.2)	13.0 (5.6–NA)		11/13 (84.6)	2 (1.7–NA)	

ATE+BEV, atezolizumab plus bevacizumab; CI, confidence interval; PS, propensity score.